Danaparoid Sodium

Danaparoid Sodium is a heparinoid representing a mixture of low-molecular weight sulfated glycosaminoglycans: heparan (not heparin) sulfate (84%), dermatan sulfate (12%), and chondroitin sulfate (4%). Danaparoid is obtained from porcine intestinal mucosa after the removal of heparin. The mean molecular weight of danaparoid is 5500 daltons. Danaparoid Sodium is used for prophylaxis of deep-vein thrombosis in patients undergoing general or orthopaedic surgery, and in the management of thromboembolic disease in patients with history of heparin-induced thrombocytopenia.

Brands
Adult Dose
Dose: 750 Xa units
Single Dose: 750 (750)
Frequency: 12 hourly
Route: SC
Instructions: Dose should begin one to four hours prior to hip replacement surgery, and then no sooner than two hours after surgery. Treatment should be continued until the risk of deep venous thrombosis has diminished, usually within seven to ten days, but may be continued for up to fourteen days.
Neonatal
Paedriatic
Dose: 400 unit/hr
Single Dose: 400 (400)
Frequency: As recommended.
Route: Maintanace dose for 5 days.
Instructions:
Characteristics
. It is of Synthetic origin. . The Molecular Weight of Danaparoid Sodium is 5500.00.
Contraindications
Danaparoid Sodium is contraindicated in conditions like Peptic ulcer,Traumatic injury,Acute musculoskeletal disorders,Relief of sore throat,Initial treatment of acute conditions,Pain management,General dose,Following coronary bypass surgery.
Effects
The symptomatic adverse reactions produced by Danaparoid Sodium are more or less tolerable and if they become severe, they can be treated symptomatically, these include Hypersensitivity reactions, Thrombocytopenia, Hemorrhage, Bruising or pain at injection site.
Indications
Danaparoid Sodium is primarily indicated in conditions like Endometrial thinning before intra-uterine surgery, Prophylaxis of venous thromboembolism.
Interactions
No data regarding the interactions of Danaparoid Sodium was found.
Interfrence
Serum test for Creatinine and Glucose
Risks
Drug should not be given to patients suffering from Liver Malfunction.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Storage
Warnings
Hepatic and renal impairment (avoid for prophylaxis if severe); pregnancy and breast-feeding. Presence of sulphite in ampoules may (especially in patients with asthma) lead to hypersensitivity (with bronchospasm and shock)
Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.